Journal
BIOACTIVE MATERIALS
Volume 5, Issue 1, Pages 92-101Publisher
KEAI PUBLISHING LTD
DOI: 10.1016/j.bioactmat.2020.01.006
Keywords
Immunosuppression; Tumor microenvironment; Peptide; Nanoparticle
Funding
- National Heart, Lung, and Blood Institute (NHLBI) [R00HL124279]
- NIH New Innovator Award [DP2DK121328]
- L.K. Whittier Foundation
- Ming Hsieh Institute for Research on Engineering-Medicine for Cancer
- Women in Science and Engineering Gabilan Assistant Professorship
- University of Southern California
Ask authors/readers for more resources
Cancer progression is marked by the infiltration of immunosuppressive cells, such as tumor-associated macrophages (TAMs), regulatory T lymphocytes (Tregs), and myeloid-derived suppressor cells (MDSCs). These cells play a key role in abrogating the cytotoxic T lymphocyte-mediated (CTL) immune response, allowing tumor growth to proceed unabated. Furthermore, targeting these immunosuppressive cells through the use of peptides and peptide-based nanomedicine has shown promising results. Here we review the origins and functions of immunosuppressive cells in cancer progression, peptide-based systems used in their targeting, and explore future avenues of research regarding cancer immunotherapy. The success of these studies demonstrates the importance of the tumor immune microenvironment in the propagation of cancer and the potential of peptide-based nanomaterials as immunomodulatory agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available